Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 1.00 |
| ▸ | GRK6 | P43250 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598226 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 | |
| SCHEMBL30598238 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 | |
| SCHEMBL14317644 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 | |
| SCHEMBL4863651 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 | |
| SCHEMBL25391024 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 | |
| SCHEMBL4873358 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 | |
| SCHEMBL25390216 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 | |
| SCHEMBL14003840 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 | |
| SCHEMBL25390414 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 | |
| SCHEMBL30598237 | 1.00 | ADK (1.00) | ADKGRK6HTTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118103711-A | Single molecule identification with reactive heterogeneous nanopores | 南京大学 | 2024-05-28 | — | — | CN | claimed |
| EP-3528815-B1 | 2,6-DIAMINOPURINE FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES CAUSED BY A NONSENSE MUTATION | MUSEUM NAT DHISTOIRE NATURELLE (FR) | 2023-06-14 | — | — | EP | claimed |
| US-11179398-B2 | Purine derivative for use in the treatment or prevention of diseases caused by a nonsense mutation | MUSÉUM NATIONAL D'HISTOIRE NATURELLE (FR) | 2021-11-23 | — | — | US | claimed |
| US-20190240228-A1 | PURINE DERIVATIVE FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES CAUSED BY A NONSENSE MUTATION | MUSÉUM NATIONAL D'HISTOIRE NATURELLE (FR) | 2019-08-08 | — | — | US | claimed |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2008-04-17 | — | — | US | claimed |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2004-04-08 | — | — | US | claimed |
| CN-118103711-A | Single molecule identification with reactive heterogeneous nanopores | 南京大学 | 2024-05-28 | — | — | CN | disclosed |
| US-11957678-B2 | Methods for inducing an immune response | MOONSHOT PHARMA LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230381152-A1 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | MOONSHOT PHARMA LLC (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230277575-A1 | Nucleoside Analogues to Inhibit the Main Protease of a Coronavirus | Institut de Recherche en Semiochimie et Ethologie Appliquee (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230277575-A1 | Nucleoside Analogues to Inhibit the Main Protease of a Coronavirus | Institut de Recherche en Semiochimie et Ethologie Appliquee (FR) | 2023-09-07 | — | — | US | disclosed |
| EP-3528815-B1 | 2,6-DIAMINOPURINE FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES CAUSED BY A NONSENSE MUTATION | MUSEUM NAT DHISTOIRE NATURELLE (FR) | 2023-06-14 | — | — | EP | disclosed |
| US-11654135-B2 | Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors | MOONSHOT PHARMA LLC (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2006044505-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1572709-A3 | USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES | PTC Therapeutics, Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1572709-A2 | USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES | PTC Therapeutics, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1534726-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC Therapeutics, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | PTC THERAPEUTICS, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004009609-A2 | NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2004009610-A2 | USE OF NUCLEOSIDE COMPOUNDS FOR NONSENSE SUPPRESSION AND THE TREATMENT OF GENETIC DISEASES | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654135-B2 | Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors | CD274, MYD88, PDCD1LG2 | ADK 1368/4885GRK6 659/4885HTT 2743/4885 |
| US-11179398-B2 | Purine derivative for use in the treatment or prevention of diseases caused by a nonsense mutation | UPF1, HPRT1, GNPDA1 | ADK 1676/4885GRK6 2414/4885HTT 2570/4885 |
| US-20230277575-A1 | Nucleoside Analogues to Inhibit the Main Protease of a Coronavirus | ACE, ACE2, METAP1 | ADK 1226/4885GRK6 4233/4885HTT 1453/4885 |
| US-20040067900-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | ADK 198/4885GRK6 3642/4885HTT 174/4885 |
| US-20080090774-A1 | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations | NSUN2, RNMT, NSUN3 | ADK 198/4885GRK6 3642/4885HTT 174/4885 |
| US-20230381152-A1 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | CD274, MYD88, PDCD1LG2 | ADK 1368/4885GRK6 659/4885HTT 2743/4885 |
| US-11957678-B2 | Methods for inducing an immune response | UPF1, RNGTT, NSUN2 | ADK 3655/4885GRK6 4083/4885HTT 1511/4885 |
| US-20190240228-A1 | PURINE DERIVATIVE FOR USE IN THE TREATMENT OR PREVENTION OF DISEASES CAUSED BY A NONSENSE MUTATION | UPF1, HPRT1, GNPDA1 | ADK 1676/4885GRK6 2414/4885HTT 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.